Strong Growth Ahead: Macular Edema and Macular Degeneration Market Size To Grow At Arecord 7.1% Cagr By 2029

The Macular Edema and Macular Degeneration Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Macular Edema and Macular Degeneration Market Size and Projected Growth Rate?
In the past few years, the market size for macular edema and macular degeneration has witnessed significant growth. The market is expected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Factors contributing to the growth during the historic period include an aging population, high prevalence of diabetes, strides made towards awareness and early diagnosis, worldwide efforts in eye health, advancements in pharmaceuticals, as well as patient advocacy and support.

The market for macular edema and macular degeneration is projected to experience robust expansion in the coming years. Its size is predicted to reach $13.71 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.1%. The forecasted growth can be associated with individualized medical treatment strategies, increased awareness in developing marketplaces, emphasis on combined therapy methods, partnership with teleophthalmology services, and the worldwide rise in elderly populations. Key trends expected in this forecast period encompass breakthroughs in prolonged-release drug delivery, incorporation of gene therapy techniques, the introduction of innovative imaging technologies, tailored therapy methods based on biomarkers, the use of teleophthalmology for distant monitoring, and progress in artificial intelligence applied to diagnostics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479

What Are the Major Segments in the Macular Edema and Macular Degeneration Market?
The macular edema and macular degeneration market covered in this report is segmented -

1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration
3) By End User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Steroid Injections, Oral Medications, Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation, Panretinal Photocoagulation (PRP), Subthreshold Laser Therapy, MicroPulse Laser Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

What Are The Driving Macular Edema and Macular Degeneration Market Evolution?
The surge in diabetes cases is anticipated to spur the growth of the macular edema and macular degeneration market. High blood sugar levels indicative of diabetes harm the eye's blood vessels, leading to macular edema and macular degeneration. For example, as reported by The National Health Service (NHS England) in June 2024, in 2023, 3,615,330 people were diagnosed with prediabetes, marking an 18% increase from 3,065,825 in 2022. Particularly alarming was the near 25% spike in cases among those under 40, with the number of afflicted individuals escalating from 173,166 in 2022 to 216,440 in 2023. This significant increase in diabetes cases is a major propellant for market growth in macular edema and macular degeneration. An upswing in eye disorders also drives growth in the macular edema and macular degeneration market. A broad spectrum of conditions falls under eye disorders which hamper the visual system and potentially lead to vision loss. These disorders can cause macular edema through fluid leakage in the macula. Furthermore, the abnormal blood vessel growth and leakage linked to wet AMD directly lead to fluid buildup in the macula. To illustrate, a report published by National Eye Health Week in September 2023 stated that the primary cause of blindness in the UK, late-stage age-related macular degeneration (AMD), is predicted to rise by 25% by 2032. Early-stage AMD (drusen) is anticipated to go up by 16%, cataracts by 25%, and glaucoma by 17% by 2032. Hence, the growing prevalence of eye disorders paves the way for the expansion of the macular edema and macular degeneration market.

Which Firms Dominate The Macular Edema and Macular Degeneration Market Segments?
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmic Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

What Trends Are Expected to Dominate the Macular Edema and Macular Degeneration Market in the Next 5 Years?
Leading businesses in the macular edema and macular degeneration sector are creating state-of-the-art products such as Vabysmo (faricimab-svoa) to bolster their market profitability. Vabysmo (faricimab-svoa) is a drug designed to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For example, in January 2022, Genentech Inc., an American biotech corporation, received Food and Drug Administration approval for Vabysmo (faricimab-svoa). This bispecific antibody targets vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), making it the first bispecific monoclonal antibody for both of these conditions. Faricimab might become a gamechanger medicine for the treatment of nAMD and DME. The FDA and EU's approval of Faricimab signifies a key achievement for Genentech and Roche.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

Which Is The Largest Region In The Macular Edema and Macular Degeneration Market?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Macular Edema and Macular Degeneration Market?
2. What is the CAGR expected in the Macular Edema and Macular Degeneration Market?
3. What Are the Key Innovations Transforming the Macular Edema and Macular Degeneration Industry?
4. Which Region Is Leading the Macular Edema and Macular Degeneration Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.